Management of patients with calciphylaxis: current perspectives

References

• Brandenburg VM, Martin H, Sohn CM, et al. [Calciphylaxis]. Dtsch Med Wochenschr. 2015;140:347–351. doi:10.1055/s-0041-100834
   Web of Science ®Google Scholar
• Weenig RH. Pathogenesis of calciphylaxis: hans Selye to nuclear factor kappa-B. J Am Acad Dermatol. 2008;58:458–471. doi:10.1016/j.jaad.2007.12.006
   PubMed Web of Science ®Google Scholar
• Mochel MC, Arakaki RY, Wang G, et al. Cutaneous calciphylaxis: a retrospective histopathologic evaluation. Am J Dermatopathol. 2013;35:582–586. doi:10.1097/DAD.0b013e31827c7f5d
   PubMed Web of Science ®Google Scholar
• Nigwekar SU, Wolf M, Sterns RH, Hix JK. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol. 2008;3:1139–1143. doi:10.2215/CJN.00530108
   PubMed Web of Science ®Google Scholar
• Weenig RH, Sewell LD, Davis MD, et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007;56:569–579. doi:10.1016/j.jaad.2006.08.065
   PubMed Web of Science ®Google Scholar
• Fernandez M, Morales E, Gutierrez E, et al. Calciphylaxis: beyond CKD-MBD. Nefrologia. 2017;37:501–507. doi:10.1016/j.nefro.2017.02.006
   Web of Science ®Google Scholar
• Mazhar AR, Johnson RJ, Gillen D, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 2001;60:324–332. doi:10.1046/j.1523-1755.2001.00803.x
   PubMed Web of Science ®Google Scholar
• Garcia-Lozano JA, Ocampo-Candiani J, Martinez-Cabriales SA, et al. An update on calciphylaxis. Am J Clin Dermatol. 2018;19:599–608. doi:10.1007/s40257-018-0361-x
   PubMed Web of Science ®Google Scholar
• Hafner J. Calciphylaxis and martorell hypertensive ischemic leg ulcer: same pattern - one pathophysiology. Dermatology. 2016;232:523–533. doi:10.1159/000448245
   Web of Science ®Google Scholar
• Kerk N, Goerge T. Livedoid vasculopathy - current aspects of diagnosis and treatment of cutaneous infarction. J Dtsch Dermatol Ges. 2013;11:407–410. doi:10.1111/ddg.12064
   Web of Science ®Google Scholar
• El-Azhary RA, Hickson L, McBane RD. Calciphylaxis. N Engl J Med. 2018;379:397–398. doi:10.1056/NEJMc1807324
   Web of Science ®Google Scholar
• Hoff NP, Homey B. [Calciphylaxis. Pathogenesis and therapy]. Hautarzt. 2011;62:509–515. doi:10.1007/s00105-010-2111-8
   Google Scholar
• Dobry AS, Ko LN, St JJ, et al. Association between hypercoagulable conditions and calciphylaxis in patients with renal disease: a case-control study. JAMA Dermatol. 2018;154:182–187. doi:10.1001/jamadermatol.2017.4920
   PubMed Web of Science ®Google Scholar
• Harris RJ, Cropley TG. Possible role of hypercoagulability in calciphylaxis: review of the literature. J Am Acad Dermatol. 2011;64:405–412. doi:10.1016/j.jaad.2009.12.007
   PubMed Web of Science ®Google Scholar
• Nigwekar SU, Kroshinsky D, Nazarian RM, et al. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. 2015;66:133–146. doi:10.1053/j.ajkd.2015.01.034
   PubMed Web of Science ®Google Scholar
• Renner R, Dissemond J, Goerge T, et al. Analysis of the German DRG data for livedoid vasculopathy and calciphylaxis. J Eur Acad Dermatol Venereol. 2017;31:1884–1889. doi:10.1111/jdv.14190
   Web of Science ®Google Scholar
• Tintut Y, Patel J, Parhami F, Demer LL. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation. 2000;102:2636–2642. doi:10.1161/01.cir.102.21.2636
   PubMed Web of Science ®Google Scholar
• Portales-Castillo I, Kroshinsky D, Malhotra CK, et al. Calciphylaxis-as a drug induced adverse event. Expert Opin Drug Saf. 2019;18:29–35. doi:10.1080/14740338.2019.1559813
   PubMed Web of Science ®Google Scholar
• Danziger J. Vitamin K-dependent proteins, warfarin, and vascular calcification. Clin J Am Soc Nephrol. 2008;3:1504–1510. doi:10.2215/CJN.00770208
   PubMed Web of Science ®Google Scholar
• Yu WY, Bhutani T, Kornik R, et al. Warfarin-associated nonuremic calciphylaxis. JAMA Dermatol. 2017;153:309–314. doi:10.1001/jamadermatol.2016.4821
   PubMed Web of Science ®Google Scholar
• Lehman JS, Chen TY, Lohse CM, et al. Evaluating the validity of subclassifying warfarin-associated nonuremic calciphylaxis: a retrospective cohort study. Int J Dermatol. 2018;57:572–574. doi:10.1111/ijd.13884
   PubMed Web of Science ®Google Scholar
• Seethapathy H, Brandenburg VM, Sinha S, et al. Review: update on the management of calciphylaxis. QJM. 2019;112:29–34. doi:10.1093/qjmed/hcy234
   PubMed Web of Science ®Google Scholar
• Zacharias JM, Fontaine B, Fine A. Calcium use increases risk of calciphylaxis: a case-control study. Perit Dial Int. 1999;19:248–252.
   PubMed Web of Science ®Google Scholar
• King BJ, El-Azhary RA, McEvoy MT, et al. Direct oral anticoagulant medications in calciphylaxis. Int J Dermatol. 2017;56:1065–1070. doi:10.1111/ijd.13685
   PubMed Web of Science ®Google Scholar
• El-Azhary RA, Arthur AK, Davis MD, et al. Retrospective analysis of tissue plasminogen activator as an adjuvant treatment for calciphylaxis. JAMA Dermatol. 2013;149:63–67. doi:10.1001/2013.jamadermatol.5
   PubMed Web of Science ®Google Scholar
• Sewell LD, Weenig RH, Davis MD, et al. Low-dose tissue plasminogen activator for calciphylaxis. Arch Dermatol. 2004;140:1045–1048. doi:10.1001/archderm.140.9.1045
   Google Scholar
• Gomes F, La FP, Costa C, et al. Non-uremic calciphylaxis: a rare diagnosis with limited therapeutic strategies. Eur J Case Rep Intern Med. 2018;5:000986.
   PubMedGoogle Scholar
• Tittelbach J, Graefe T, Wollina U. Painful ulcers in calciphylaxis - combined treatment with maggot therapy and oral pentoxyfillin. J Dermatolog Treat. 2001;12:211–214. doi:10.1080/09546630152696035
   PubMed Web of Science ®Google Scholar
• Sattler DR, Preiss S, Altmann S, et al. [The plastic surgical treatment of progressive skin lesions caused by calciphylaxis]. Zentralbl Chir. 2011;136:621–624. doi:10.1055/s-0031-1271458
   Web of Science ®Google Scholar
• Latus J, Kimmel M, Ott G, et al. Early stages of calciphylaxis: are skin biopsies the answer? Case Rep Dermatol. 2011;3:201–205. doi:10.1159/000333007
   Google Scholar
• Ross EA. Evolution of treatment strategies for calciphylaxis. Am J Nephrol. 2011;34:460–467. doi:10.1159/000332221
   PubMed Web of Science ®Google Scholar
• An J, Devaney B, Ooi KY, et al. Hyperbaric oxygen in the treatment of calciphylaxis: a case series and literature review. Nephrology (Carlton). 2015;20:444–450. doi:10.1111/nep.12433
   PubMed Web of Science ®Google Scholar
• Dado DN, Huang B, Foster DV, et al. Management of calciphylaxis in a burn center: a case series and review of the literature. Burns. 2019;45:241–246. doi:10.1016/j.burns.2018.09.008
   PubMed Web of Science ®Google Scholar
• Brandenburg VM, Kramann R, Rothe H. et al. Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol Dial Transplant. 2016. gfv438. doi:10.1093/ndt/gfv438
   Web of Science ®Google Scholar
• Chan MR, Ghandour F, Murali NS, et al. Pilot study of the effect of lanthanum carbonate (Fosrenol(R)) in patients with calciphylaxis: a Wisconsin Network for Health Research (WiNHR) study. J Nephrol Ther. 2014;4:1000162. doi:10.4172/2161-0959.1000162
   Google Scholar
• Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS. The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: the EVOLVE trial. Clin J Am Soc Nephrol. 2015;10:800–807. doi:10.2215/CJN.10221014
   PubMed Web of Science ®Google Scholar
• Girotto JA, Harmon JW, Ratner LE, Nicol TL, Wong L, Chen H. Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. Surgery. 2001;130:645–650. doi:10.1067/msy.2001.117101
   PubMed Web of Science ®Google Scholar
• Duffy A, Schurr M, Warner T, Chen H. Long-term outcomes in patients with calciphylaxis from hyperparathyroidism. Ann Surg Oncol. 2006;13:96–102. doi:10.1245/ASO.2006.03.042
   Web of Science ®Google Scholar
• Deen J, Schaider H. The use of cinacalcet for the treatment of calciphylaxis in patients with chronic kidney disease: a comprehensive review. Australas J Dermatol. 2019. doi:10.1111/ajd.12992
   Web of Science ®Google Scholar
• Ferrer MD, Perez MM, Canaves MM, et al. A novel pharmacodynamic assay to evaluate the effects of crystallization inhibitors on calcium phosphate crystallization in human plasma. Sci Rep. 2017;7:6858. doi:10.1038/s41598-017-07203-x
   Web of Science ®Google Scholar
• Ross EA. What is the role of using sodium thiosulfate or bisphosphonates in the treatment for calciphylaxis? Semin Dial. 2011;24:434–436. doi:10.1111/j.1525-139X.2011.00954.x
   Web of Science ®Google Scholar
• Schliep S, Schuler G, Kiesewetter F. Successful treatment of calciphylaxis with pamidronate. Eur J Dermatol. 2008;18:554–556. doi:10.1684/ejd.2008.0499
   Web of Science ®Google Scholar
• Torregrosa JV, Duran CE, Barros X, et al. Successful treatment of calcific uraemic arteriolopathy with bisphosphonates. Nefrologia. 2012;32:329–334. doi:10.3265/Nefrologia.pre2012.Jan.11137
   Web of Science ®Google Scholar
• Peng T, Zhuo L, Wang Y, et al. Systematic review of sodium thiosulfate in treating calciphylaxis in chronic kidney disease patients. Nephrology (Carlton). 2018;23:669–675. doi:10.1111/nep.13081
   PubMed Web of Science ®Google Scholar
• Devey S, Valois A, Cazajous G, et al. [Calciphylaxis in hemodialysis patients: 8 cases treated with sodium thiosulfate]. Ann Dermatol Venereol. 2018;145:288–292. doi:10.1016/j.annder.2018.02.002
   Web of Science ®Google Scholar
• Bourgeois P, De HP. Sodium thiosulfate as a treatment for calciphylaxis: a case series. J Dermatolog Treat. 2016;27:520–524. doi:10.3109/09546634.2016.1163316
   PubMed Web of Science ®Google Scholar
• Isoherranen K, Bouchard L, Kluger N. Benefits of intralesional injections of sodium thiosulfate in the treatment of calciphylaxis. Int Wound J. 2017;14:955–959. doi:10.1111/iwj.12738
   PubMed Web of Science ®Google Scholar